Date: 2017-09-28
Type of information: Licensing agreement
Compound: cancer immunotherapy targeting a new suppressive myeloid cell receptor (a C-type lectin receptor)
Company: OSE Immunotherapeutics (France) Inserm Transfert (France)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: immunotherapy product
Disease:
Details:
- • On September 28, 2017, OSE Immunotherapeutics announced that the company has entered into an agreement with Inserm Transfert, on behalf of Inserm, a French public organization dedicated to human health, and Nantes University, to collaborate on the development of a cancer immunotherapy targeting a new suppressive myeloid cell receptor (a C-type lectin receptor). This agreement includes a worldwide and exclusive license option for OSE to further develop any product candidate emerging from this collaboration following the planned conclusion of the partnership.
- This research collaboration will focus on the development of an antibody that targets a newly identified C-type lectin receptor to block suppressive functions of myeloid cells and to restore anti-tumor response of T-lymphocytes. Suppressive myeloid cells have the ability to accumulate in the tumor microenvironment and to deregulate the immune activation of T-lymphocytes. This new target was discovered by Dr. Elise Chiffoleau during her research on the mechanisms of immune
tolerance in transplantation. Dr. Chiffoleau is a member of the research team led by Pr. Régis Josien, Director of the Center for Research in Transplantation and Immunology of Nantes (UMR 1064, Inserm, Nantes University).
Financial terms:
Latest news:
Is general: Yes
